Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Rhea-AI Summary
Journey Medical (Nasdaq: DERM) expanded payer access for Emrosi™, increasing commercial lives reached from approximately 100 million to over 150 million as of April 1, 2026.
Approximately 85% of U.S. commercial lives now have access after contracting with a third major GPO. The company expects expanded access to support prescription growth and improved brand profitability as formulary adoption progresses through 2026.
Positive
- Payer reach expanded from ~100M to >150M commercial lives
- 85% of U.S. commercial lives now have access to Emrosi
- Contracts secured with three major GPOs for Emrosi
Negative
- Formulary adoption and conversion of access into coverage remain in progress through 2026
News Market Reaction – DERM
In the Apr 21 session, DERM declined 5.20%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Full-year 2025 earnings | Positive | -30.0% | Reported revenue growth to $61.9M and Emrosi net revenues of $14.7M. |
| Mar 18 | Earnings date notice | Neutral | -5.1% | Announced timing and webcast details for year-end 2025 earnings release. |
| Dec 10 | Emrosi Phase 1 data | Positive | -5.3% | Published positive Phase 1 Emrosi microbiome study showing no significant safety issues. |
| Nov 12 | Q3 2025 earnings | Positive | -15.3% | Reported $17.6M net revenues and positive adjusted EBITDA driven by Emrosi. |
| Nov 05 | Earnings call notice | Neutral | -1.8% | Set date and call details for Q3 2025 financial results and corporate update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and earnings updates have repeatedly been followed by negative 1-day price reactions, suggesting a pattern of weak trading responses to fundamentally constructive news.
Over the last six months, Journey Medical has focused on scaling Emrosi™ and improving financial metrics. Q3 2025 results on Nov 12, 2025 showed $17.6M in net revenues with Emrosi contributing $4.9M, yet the stock fell 15.31%. Full-year 2025 results on Mar 25, 2026 reported revenues of $61.9M and Emrosi net revenues of $14.7M, but shares declined 30.01%. Even a positive Phase 1 Emrosi microbiome study on Dec 10, 2025 coincided with a 5.29% drop. Against this backdrop, today’s expansion of Emrosi’s commercial access continues a series of seemingly positive product milestones contrasted with historically weak short-term price reactions.
Key Terms
group purchasing organization financial
gpo financial
modified-release medical
immediate release medical
extended release medical
rosacea medical
formulary medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026
SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that approximately
“We are extremely pleased with the completion of this milestone for Emrosi™,” said Claude Maraoui, Co-Founder, President, and CEO of Journey Medical Corporation. “Our focus on delivering cost-effective access to high-quality dermatology therapies is expected to expand coverage and improve patient access, positioning Emrosi™ for sustained commercial growth. Now that our contracts have been secured with the three major GPOs, we look forward to continuing to increase coverage for Emrosi™ for patients nationwide by converting access into coverage. Our efforts remain on health plan formulary adoption, on both a national and regional level, throughout 2026 and beyond, supporting Emrosi’s™ potential to become the standard of care in rosacea and driving long-term value creation. As formulary adoption continues to increase, we expect there to be less reliance on our co-pay bridging program and an improvement in profitability for the brand.”
About Rosacea
Rosacea is a chronic, relapsing, inflammatory skin condition that most commonly presents with symptoms such as deep facial redness, acne-like inflammatory lesions (papules and pustules) and spider veins (telangiectasia). According to The National Rosacea Society, it is estimated that rosacea affects over 17 million Americans and as many as 415 million people worldwide. Rosacea is most frequently seen in adults between 30 and 50 years of age. Surveys conducted by The National Rosacea Society report that more than 90 percent of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41 percent stated that it had caused them to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder had adversely affected their professional interactions, and 51 percent said they had missed work because of their condition.
Important Safety Information
Indication: EMROSI™ is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Adverse Events: The most common adverse reaction reported by ≥
For full prescribing information, please visit www.emrosi.com.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the Company”, “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate,” “believe,” “continue,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “intend,” “potential” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and future product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition because their period of exclusivity has ended or they are without patent protection, subjecting them to the potential introduction of new competitor products and/or an increase in market share of existing competitor products, either of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance on third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of EmrosiTM and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
